Impact of removing mucosal barrier injury laboratory-confirmed bloodstream infections from central line-associated bloodstream infection rates in the National Healthcare Safety Network, 2014

Isaac See; Minn M Soe; Lauren Epstein; Jonathan R Edwards; Shelley S Magill; Nicola D Thompson

doi:10.1016/j.ajic.2016.10.015

Impact of removing mucosal barrier injury laboratory-confirmed bloodstream infections from central line-associated bloodstream infection rates in the National Healthcare Safety Network, 2014

Am J Infect Control. 2017 Mar 1;45(3):321-323. doi: 10.1016/j.ajic.2016.10.015. Epub 2016 Nov 14.

Authors

Isaac See¹, Minn M Soe², Lauren Epstein², Jonathan R Edwards², Shelley S Magill², Nicola D Thompson²

Affiliations

¹ Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA. Electronic address: gst8@cdc.gov.
² Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA.

Abstract

Central line-associated bloodstream infection (CLABSI) event data reported to the National Healthcare Safety Network from 2014, the first year of required use of the mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) definition, were analyzed to assess the impact of removing MBI-LCBI events from CLABSI rates. CLABSI rates decreased significantly in some location types after removing MBI-LCBI events, and MBI-LCBI events will be removed from publicly reported CLABSI rates.

Keywords: Central line–associated bloodstream infection; Oncology; Public reporting; Surveillance.

Published by Elsevier Inc.

MeSH terms

Catheter-Related Infections / epidemiology*
Catheterization, Central Venous / adverse effects*
Humans
Mucous Membrane / injuries*
Prevalence
Sepsis / epidemiology*
Sepsis / etiology*

Grants and funding

CC999999/Intramural CDC HHS/United States